Impact Biomedical (IBO) Payables (2022 - 2026)
Impact Biomedical's (IBO) quarterly Payables came in at $374000.0 in Q1 2026, down 96.17% YoY from $9.8 million in Q1 2025, and up 7.78% on a QoQ basis from $347000.0 in Q4 2025.
Impact Biomedical (IBO) Payables (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Payables data on file, last reported at $374000.0 in Q1 2026.
- Quarterly Payables fell 96.17% year-over-year to $374000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $374000.0 (down 96.17% YoY) and the FY2025 annual result came in at $347000.0, down 96.38% from the prior year.
- Payables improved to $374000.0 in Q1 2026, from $347000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $23.5 million in Q3 2025 to a low of $347000.0 in Q4 2025.
- A 5-year average of $11.0 million and a median of $12.1 million in 2023 frame the typical range for Payables.
- The widest YoY moves for Payables: up 2164.19% in 2025, down 96.38% in 2025.
- Tracing IBO's Payables over 5 years: stood at $10.5 million in 2022, then advanced by 22.56% to $12.9 million in 2023, then decreased by 25.69% to $9.6 million in 2024, then sank by 96.38% to $347000.0 in 2025, then gained by 7.78% to $374000.0 in 2026.
- The last three Payables figures came in at $374000.0 (Q1 2026), $347000.0 (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 467,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 467,000.00 |
| Mar 31, 2026 | 374,000.00 |
| Dec 31, 2025 | 347,000.00 |
| Sep 30, 2025 | 23.46 Mn |
| Jun 30, 2025 | 22.91 Mn |
| Mar 31, 2025 | 9.76 Mn |
| Dec 31, 2024 | 9.59 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 14.44 Mn |
| Mar 31, 2024 | 13.81 Mn |
| Dec 31, 2023 | 12.91 Mn |
| Sep 30, 2023 | 12.26 Mn |
| Jun 30, 2023 | 12.06 Mn |
| Dec 31, 2022 | 10.53 Mn |